Akums Drugs and Pharmaceuticals has launched a new sterile facility designed to produce lyophilised products, injectables, vials, ampoules, eye and ear drops, and form-fill-seal (FFS) products.

 The facility's establishment aims to address the rising global demand for lyophilised drugs, a market projected to grow from USD 3,365.4 million in 2023 to USD 4,978.3 million by 2030, with a compound annual growth rate (CAGR) of 5.6 percent. The increasing preference for pharmaceutical products requiring greater stability and extended shelf life underpins this growth. 

Akums' new facility is part of its broader strategy to expand capacity. The company aims to innovate and address specialised therapeutic needs across diverse areas.  This move signals Akums' entry into the highly specialised lyophilisation segment, which involves removing water from drug particles at freezing temperatures to enhance stability, shelf life, and value. This development positions Akums as a key player in the expanding market for lyophilised and injectable pharmaceutical products.

Managing Director of Akums Drugs and Pharmaceuticals, Sanjeev Jain, emphasised the facility's role in meeting global demand with a commitment to "the highest standards of quality and safety."